The positive market reaction is likely due to investors' optimism about the potential of Prime Editing technology to advance Prime Medicine's programs. The announcement of presenting this data at scientific meetings is seen as a significant step forward, indicating progress in their research and development efforts. This progress is typically viewed favorably by investors, as it suggests the company is moving closer to realizing the commercial potential of its technology, which could lead to future revenue growth.